|1.||Joyce, Jeffrey N: 2 articles (02/2010 - 02/2010)|
|2.||Der, Terry C: 2 articles (02/2010 - 02/2010)|
|3.||Millan, M J: 2 articles (07/2004 - 06/2000)|
|4.||Yarkov, Alex V: 1 article (02/2010)|
|5.||Iarkov, Alex V: 1 article (02/2010)|
|6.||Mela, Flora: 1 article (02/2010)|
|7.||Millan, Mark J: 1 article (02/2010)|
|8.||Morari, Michele: 1 article (02/2010)|
|9.||Brocco, Mauricette: 1 article (02/2010)|
|10.||Gyertyán, István: 1 article (10/2007)|
07/01/2004 - "Administered alone, S33084 exerted a modest, but significant, anti-parkinsonian effect without provoking dyskinesia. "
02/01/2010 - "In the present study, we investigated whether the selective D(3) receptor antagonist, S33084, affects development and expression of abnormal involuntary movements (AIMs), a behavioural correlate of dyskinesia, in rats hemi-lesioned with 6-hydroxydopamine and chronically treated with L-DOPA. "
02/01/2010 - "The selective D(3) receptor antagonist, S33084, improves parkinsonian-like motor dysfunction but does not affect L-DOPA-induced dyskinesia in 6-hydroxydopamine hemi-lesioned rats."
07/01/2004 - "At these doses, S33084 did not significantly modify levodopa-induced or ropinirole-induced dyskinesia. "
07/01/2004 - "S33084 was administered to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned marmosets previously primed with levodopa to elicit dyskinesia. "
06/01/2000 - "Moreover, S33084 was inactive in models of potential extrapyramidal activity in rats: induction of catalepsy and prolactin secretion and inhibition of methylphenidate-induced gnawing. "
10/31/2007 - "The selective dopamine D3 receptor antagonists, SB 277011-A and S 33084 block haloperidol-induced catalepsy in rats."
|3.||Body Weight (Weight, Body)
02/10/2010 - "D(3)R KO and WT mice were administered vehicle (saline, 1 ml/100g body weight, i.p.), or S33084 (1.0mg/kg.) and U99194A (0.1mg/kg or 0.01 mg/kg), and horizontal and vertical activity counts were recorded for 30 min. Mice were then treated with vehicle or MK-801 (0.12 mg/kg i.p.) and returned to the open field for an additional 55 min. D(3)R KO mice showed a significantly higher level of locomotor and rearing activity during the 1st 30 min after vehicle treatment compared to WT mice. "
02/10/2010 - "Mice were administered vehicle (saline, 1 ml/100g body weight, i.p.), or dopamine D(3) receptor preferring antagonists 3aR,9bS)-N[4-(8-cyano-1,3a,4,9b-tetrahydro-3H-benzopyrano[3,4-c]pyrrole-2-yl)-butyl] (4-phenyl) benzamide) (S33084, 1.0mg/kg, i.p.) and 5,6-dimethoxy-2(dipropylamino)indan (U99194A, 5.0 mg/kg i.p.), and immediately placed into the open field apparatus. "
06/01/2000 - "Another selective D(3) antagonist, GR218,231, mimicked S33084 in inhibiting 7-OH-DPAT-induced PEs and hypothermia but neither hypophagia nor yawning behavior. "
06/01/2000 - "The selective dopamine D(3)-receptor antagonist S33084 dose dependently attenuated induction of hypothermia by 7-hydroxy-2-dipropylaminotetralin (7-OH-DPAT) and PD128,907. "
|1.||Levodopa (L Dopa)
|2.||Oxidopamine (6 Hydroxydopamine)
|4.||Dopamine D3 Receptors
|5.||Dizocilpine Maleate (Dizocilpine)
|6.||1- Methyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (MPTP)